Introduction
============

Inherited retinal dystrophies (IRDs) are a group of clinically and genetically heterogeneous disorders leading to vision loss because of degeneration of retinal cells \[[@r1]-[@r5]\]. Mutations in more than 250 genes have been reported to cause [IRDs](https://sph.uth.edu/retnet/). Most identified mutations are inherited in an autosomal recessive fashion (50--60%) although some can be autosomal dominant (30--40%), X-linked (2--20%), or mitochondrial \[[@r6]\]. IRDs are divided into non-syndromic forms, such as retinitis pigmentosa (RP), cone-rod dystrophy (CRD), Leber congenital amaurosis (LCA), and Stargardt disease (STGD1), as well as syndromic forms \[[@r7]\]. These inherited retinal dystrophies have an estimated incidence of 1:2,000 individuals \[[@r4]\].

The earliest clinical symptoms of RP (OMIM [268000](https://www.ncbi.nlm.nih.gov/omim/?term=268000)) are night blindness and peripheral vision loss (tunnel vision) due to rod cell degeneration. In later stages of the disease, central vision can also be lost once cone cells degenerate, and eventually, patients with RP can become (legally) blind \[[@r6],[@r8]\]. In CRD (OMIM [120970](https://www.ncbi.nlm.nih.gov/omim/?term=120970)), the main manifestations are loss of visual acuity, color vision, and photophobia followed by night blindness and tunnel vision \[[@r9]\]. The rarest and most severe retinal dystrophy form is LCA (OMIM [204000](https://www.ncbi.nlm.nih.gov/omim/?term=204000)), in which patients have severe visual impairment in the first year of life \[[@r10]\]. LCA appears with severe and early visual loss, nystagmus, and sluggish pupils \[[@r11]\]. STGD1 (OMIM [248200](https://www.ncbi.nlm.nih.gov/omim/?term=248200)) is one of the most common macular degenerative disorders with the features of macular atrophy, impaired central vision, and decreased visual acuity. Color vision, especially a red-green defect, is apparent in most affected individuals \[[@r12]\].

Because of the complexity of IRDs, it is often necessary to reconcile the clinical diagnosis, family diagnosis, and molecular diagnosis. This can be done in a multidisciplinary team which ideally includes trained ophthalmologists, genetic counselors, and molecular geneticists. Thus, identification of the pathogenic DNA variants can help clinicians and health professionals to improve and expedite the diagnosis of the disease and provide patients and their families with more accurate genetic counseling. Moreover, increasing knowledge of the molecular mechanisms involved in IRD pathogenesis may also lead to the development of new treatment options for affected individuals in the future \[[@r13]\].

Since the introduction of next-generation sequencing (NGS), several different targeted gene panel tests that sequence a large set of disease-associated genes have been developed for specific inherited eye disorders \[[@r14]\]. In this study, we applied a targeted gene panel--based NGS approach based on molecular inversion probes (MIPs) to obtain a molecular diagnosis for 50 patients who had been diagnosed with IRDs and for whom no genetic tests had been performed previously. Using this method, variants in 108 genes associated with non*-*syndromic IRDs were screened.

Methods
=======

Subjects
--------

In this study, we included 50 IRD probands with Iranian origin and the clinical diagnosis of RP (n=31), CRD (n=5), LCA (n=11), or STGD1 (n=3) who had not been genetically investigated previously. The clinical diagnosis was established by a trained ophthalmologist including the patient pedigree and history of the disease, electroretinography (MonPack3; Metrovision, Perenchies, France), evaluation of visual acuity using slit-lamp biomicroscopy, and fundoscopy (TRC-50EX retinal camera; Topcon, Tokyo, Japan). Written informed consent was obtained from all study subjects. This study was approved by the institutional review board of the ethics committee of Isfahan Medical University, Iran. The study adhered to the tenets of the Declaration of Helsinki and the ARVO statement on human subjects was approved by the institutional review board of the ethics committee of Isfahan Medical University, Iran.

Targeted sequencing and genetic analysis
----------------------------------------

Five cc of peripheral blood samples of affected and unaffected members were collected and mixed with EDTA anticoagulant (Merck KGaA, Darmstadt, Germany). Genomic DNA of all samples was extracted using the phenol-chloroform method \[[@r15]\].

Targeted NGS was performed to identify the genetic etiology of IRDs in 50 patients with different types of IRDs. The 108 gene panel MIP analysis designed at the Department of Human Genetics at Radboud University Medical Center (Nijmegen, The Netherlands) consisted of genes implicated in non-syndromic achromatopsia, cone dystrophy (CD) and CRD (autosomal dominant, autosomal recessive, and X-linked), congenital stationary night blindness (autosomal recessive and X-linked), macular degeneration (autosomal recessive and autosomal dominant), LCA (autosomal dominant and autosomal recessive), RP (autosomal recessive, autosomal dominant, and X-linked), and choroideremia. MIPs with 5-bp molecular tags were used to perform targeted NGS of 108 genes associated with IRD (Appendix 1). The 1,524 coding exons and at least 10 bp flanking each exon were targeted using 6,129 MIPs for an overall target size of 647,574 bp. On average, four to six MIPs cover one exon. When known single nucleotide polymorphisms (SNPs) resided in the genomic regions complementary to the annealing or ligation arm, SNP-specific MIPs were designed. The panel also included the frequent LCA-associated pathogenic intronic variant c.2992+1655A\>G in *CEP290*(Gene ID 80184, OMIM [610142](https://www.ncbi.nlm.nih.gov/omim/?term=610142)) \[[@r16]\], as well as five deep-intronic variants in *ABCA4* (Gene ID 496442, OMIM [248200](https://www.ncbi.nlm.nih.gov/omim/?term=248200)) \[[@r17]\]. Pooled and phosphorylated probes were added to the capture reactions with 100 ng of genomic DNA from each individual to produce a sequence library for each individual. The libraries were amplified with 21 cycles of PCR (first denaturation step at 95 ºC for 4 min, followed by 21 cycles at 94 ºC for 30 s, 57 ºC for 30 s, 72 ºC for 1 min and then a final extension step at 72 ºC for 5 min), during which an 8-bp sample barcode was introduced. The barcoded libraries were then pooled and purified with AMPPureXP beads (Beckman-Coulter, Indianapolis, IN). Sequencing was performed on an Illumina NextSeq 500 system (San Diego, CA). Demultiplexed BAM files were aligned to a human reference sequence ([UCSC](https://genome.ucsc.edu/) Genome Browser hg19) via the Burrows-Wheeler Aligner (BWA) v.0.6.2 \[[@r18]\]. In-house automated data analysis pipeline and variant interpretation tools were used for variant calling. Only non-synonymous single nucleotide variants (nsSNVs), nonsense variants, putative splice site (±10 bps) variants, insertions, duplications, and deletions represented by more than 20 sequence reads were considered for further analysis. In addition, variants with a minor allele frequency (MAF) \>0.5% in the Exome Aggregation Consortium Database (ExAC) Version 0.3.1 \[[@r19]\] were excluded from further investigation, with the exception of a few frequent variants in *ABCA4* (i.e., c.2588G\>C, c.5882G\>A, and c.5603A\>T \[[@r20]-[@r25]\]) that were selected separately.

In silico predictions
---------------------

Several criteria were taken into account to evaluate the potential pathogenicity of variants: 1) The variants had previously been reported to be pathogenic, 2) the variants were absent in the ExAC database or showed a low MAF (\<0.5%), 3) the variants caused a loss-of-function (LOF) of the encoded protein, such as nonsense, canonical splice site, and frameshift mutations, and 4) missense variants were predicted to be damaging by in silico prediction algorithms. The pathogenicity prediction tools used for missense variants were [PolyPhen-2](http://genetics.bwh.harvard.edu/pph2/), Sorting Intolerant From Tolerant ([SIFT](http://sift.bii.a-star.edu.sg/)), PhyloP score, the [Grantham score](http://www.mutationtaster.org/), Mutation Taster, and Combined Annotation Dependent Depletion ([CADD](http://cadd.gs.washington.edu/score)) score assessment. For the selection of non-canonical splice site variants, in silico predictions were performed by using five algorithms (SpliceSiteFinder-like, MaxEntScan, NNSPLICE, GeneSplicer, and Human Splicing Finder) via Alamut Visual software version 2.7 \[[@r26]--[@r30]\], and Biosoftware ([Interactive Biosoftware](http://www.interactive-biosoftware.com), Rouen, France), by comparing the splicing scores for wild-type and variant nucleotides.

Segregation analysis
--------------------

Candidate variants were validated and tested for cosegregation within the families using Sanger sequencing. For this purpose, specific primers were designed for PCR amplification of fragments containing the identified candidate causal mutations in each patient. PCR amplicons were sequenced using Sanger sequencing on an ABI 3730 DNA analyzer (Cologne, Germany) with BigDye chemistry v3.1.

Results
=======

Study population
----------------

Fifty unrelated Iranian patients with non-syndromic IRD were included in this study, and their parents were first (34 families) or second cousins (16 families). All clinical information for the 50 families is summarized in [Table 1](#t1){ref-type="table"}. Among the 50 patients, 31 have RP, five have CRD, 11 have LCA, and three have STGD1.

###### Clinical information overview for 50 Iranian families with inherited retinal dystrophies.

  Diagnosis     Symptoms                                                                                                               Number of patients     Sex        Mean age of onset (±SD)     Mean age (±SD)     Family history of IRDs   
  ------------- ---------------------------------------------------------------------------------------------------------------------- ---------------------- ----- ---- --------------------------- ------------------ ------------------------ ----
  RP            NB, Tunnel vision, near blindness                                                                                      31                     15    16   11.6±4.2 years              31.5±6.3 years     21                       10
  CRD           Photophobia, defect in color vision, near blindness                                                                    5                      1     4    11.7± 4.2 years             31.7±6.3 years     4                        1
  LCA           Nystagmus and total blindness                                                                                          11                     7     4    9.6±2.08 months             31.3±6.7 years     7                        4
  STGD1         Photophobia, defect in color vision, difficulty in adaption to the dark after sunlight exposure, central vision loss   3                      0     3    11.2±5.1 years              30.6±2.5 years     2                        1

NB: Night blindness, RP: Retinitis pigmentosa, CRD: Cone-rod dystrophy, LCA: Leber congenital amaurosis, STGD1: Stargardt disease, IRD: Inherited retinal dystrophies, SD: Standard deviation

Variant prioritization to identify causal variants
--------------------------------------------------

One affected individual from each of the 50 families was subjected to targeted NGS of 108 known IRD-associated genes (Appendix 1). The averages of 1.2 million reads on target per sample were obtained using our capture panel technology, with an average coverage of 213 reads per MIP. Moreover, an average of 88% of targeted regions had 10X coverage or more, which was sufficient for accurate variant calling. The pipeline initially called an average of 532 single nucleotide variants and 64 insertions or deletions for each sample. In this study, putative pathogenic variants were identified in 36 index cases ([Table 2](#t2){ref-type="table"}), and we could not find the pathogenic variants for the remaining 14 families. All putative disease-associated variants were validated with conventional Sanger sequencing, and segregation analysis was performed for all 36 families with identified pathogenic variants. Homozygosity was observed for 32/36 patients (88%), and four patients were compound heterozygous.

###### Pathogenic variants identified by targeted next-generation sequencing in 36 Iranian probands affected with IRDs.

  Index ID                Gene        [Refseq]{.ul}    Phenotype   Exon/Intron   Nucleotide change   Protein change        Zygosity       [Reference]{.ul}
  ----------------------- ----------- ---------------- ----------- ------------- ------------------- --------------------- -------------- ------------------
  066,592                 *ABCA4*     *NM_000350*      STGD1       E1            c.1A\>G             p.(Met1?)             Homo           \[[@r31]\]
  066,595                 *ABCA4*     *NM_000350*      STGD1       I43           c.6005+1G\>A        p.?                   Compound het   \[[@r32]\]
  066,595                 *ABCA4*     *NM_000350*      STGD1       E6            c.634C\>T           p.(Arg212Cys)         Compound het   \[[@r33]\]
  066,599                 *ABCA4*     *NM_000350*      STGD1       E30           c.4462T\>C          p.(Cys1488Arg)        Compound het   \[[@r34]\]
  066,599                 *ABCA4*     *NM_000350*      STGD1       E8            c.913C\>T           p.(Gln305\*)          Compound het   \[[@r35]\]
  066,854                 *ABCA4*     *NM_000350*      RP          E46           c.6385A\>G          p.(Ser2129Gly)        Homo           \[[@r36]\]
  066,863                 *ABCA4*     *NM_000350*      RP          I20           c.3051--2A\>G       p.?                   Homo           Novel
  066,876                 *ABCA4*     *NM_000350*      RP          I27           c.4128+1G\>A        p.?                   Homo           Novel
  066,877                 *AIPL1*     *NM_014336*      LCA         E6            c.834G\>A           p.(Trp278\*)          Homo           \[[@r37]\]
  066,872                 *BBS1*      *NM_024649*      RP          E5            c.479G\>A           p.(Arg160Gln)         Homo           \[[@r38]\]
  066,568                 *BBS2*      *NM_031885*      RP          E14           c.1705C\>T          p.(Gln569\*)          Compound het   Novel
  066,568                 *BBS2*      *NM_031885*      RP          I1            c.117+1G\>T         p.?                   Compound het   Novel
  066,574                 *BBS2*      *NM_031885*      RP          E2            c.224T\>G           p.(Val75Gly)          Homo           \[[@r39]\]
  066,891                 *CEP290*    *NM_025114*      LCA         E54           c.7304T\>G          p.(Val2435Gly)        Homo           Novel
  066,871                 *CERKL*     *NM_001030311*   RP          E6            c.847C\>T           p.(Arg283\*)          Homo           \[[@r40]\]
  066,889;066892          *CERKL*     *NM_001030311*   CRD, RP     E13           c.1453_1454insA     p.(Pro485Hisfs\*4)    Homo           Novel
  066,880                 *CRB1*      *NM_201253*      RP          E7            c.2234C\>T          p.(Thr745Met)         Homo           \[[@r41]\]
  066,886                 *CRB1*      *NM_201253*      RP          E2            c.548G\>A           p.(Cys183Tyr)         Homo           Novel
  066,607                 *GUCY2D*    *NM_000180*      LCA         E12           c.2383C\>T          p.(Arg795Trp)         Homo           Novel
  066,858                 *GUCY2D*    *NM_000180*      LCA         E4            c.1216G\>C          p.(Asp406His)         Homo           Novel
  066,855                 *LCA5*      *NM_001122769*   RP          E4            c.720+1G\>A         p.?                   Homo           \[[@r42]\]
  066,852                 *LRAT*      *NM_004744*      RP          E2            c.487C\>G           p.(His163Asp)         Homo           Novel
  066,853                 *LRAT*      *NM_004744*      RP          E2            c.157_159dup        p.(Val53dup)          Homo           Novel
  066,882                 *MERTK*     *NM_006343*      RP          E2            c.390G\>A           p.(Trp130\*)          Homo           \[[@r43]\]
  066,867                 *PDE6B*     *NM_000283*      RP          E5            c.782_784del        p.(Phe261del)         Homo           Novel
  066,884                 *PDE6C*     *NM_006204*      CRD         E12           c.1612T\>A          p.(Phe538Ile)         Homo           Novel
  066,887                 *PDZD7*     *NM_001195263*   RP          E6            c.793A\>G           p.(Arg265Gly)         Homo           Novel
  066,865                 *PROM1*     *NM_006017*      RP          E25           c.2461C\>T          p.(Arg821\*)          Homo           Novel
  066,859                 *RP1*       *NM_006269*      RP          E4            c.2749C\>T          p.(Gln917\*)          Homo           Novel
  066,885                 *RP1*       *NM_006269*      RP          E4            c.1498_1499del      p.(Met500Valfs\*7)    Compound het   \[[@r44]\]
  066,885                 *RP1*       *NM_006269*      RP          E4            c.4105C\>T          p.(Gln1369\*)         Compound het   \[[@r40]\]
  066,860                 *RPE65*     *NM_000329*      RP          E12           c.1299T\>A          p.(Tyr433\*)          Homo           Novel
  066,864;066869          *RPE65*     *NM_000329*      RP          E10           c.1102T\>C          p.(Tyr368His)         Homo           \[[@r45]\]
  066,879                 *RPE65*     *NM_000329*      RP          I4            c.354--1G\>A        p.?                   Homo           Novel
  066,584;066866;066868   *RPGRIP1*   *NM_020366*      CRD, LCA    E10           c.1306G\>T          p.(Ala436Ser)         Homo           Novel
  066,878                 *SPATA7*    *NM_018418*      RP          E6            c.506del            p.(Thr169Lysfs\*25)   Homo           Novel

Overall, we identified 36 unique pathogenic variants based on the low allele frequency or absence of variants in ExAC, their high evolutionary conservation, the type of the amino acid substitutions, and the high predicted impacts of an amino acid substitution on the structure and function of a human protein in 19 genes. Of these, 20 were novel with the remaining 16 previously reported as IRD-causing variants \[[@r31]-[@r45]\]. Furthermore, 14 out of the 50 families remained genetically unexplained (Figure 1). Thus, the sensitivity of the gene panel for detection rate was 72%. The unique variants comprised 15 missense variants, nine nonsense variants, three deletions or insertions leading to a frameshift, six canonical splice site variants, two in-frame deletion and duplications, and one start loss. Pathogenicity was interpreted in accordance with different predictions (Table 3). According to the prediction tools in this study, all variants were annotated as pathogenic except one missense variant in *ABCA4* (c.6385A\>G; p.(Ser2129Gly)) that is predicted to be benign by PolyPhen-2 and tolerated by SIFT. However, this variant was predicted to be disease causing by MutationTaster and a high CADD score. As shown in Appendix 1, this variant is situated at the penultimate position of exon 46 and is part of the splice donor site consensus sequence. The canonical splice site nucleotides are GC, and therefore, the corresponding splice site was recognized only by SpliceSiteFinder-like. It predicted a strength of 91.8 (on a scale from 0 to 100) for the wild-type sequence and 80.3 for the mutant c.6385A\>G, which is considered a large decrease in splice strength. Accordingly, we included the p.? in the predicted protein change. In addition, this homozygous variant has not been reported in ExAC.

Discussion
==========

Although consanguineous marriages are common in the Iranian population \[[@r46]\], which makes the Iranian gene pool a valuable asset for genetic studies, little is known about inherited retinal degeneration in the Iranian community. Overall, 37.4% of Iranian marriages are consanguineous. Among them, 19.3% are first cousins and 18.1% second cousins \[[@r47]\]. Thus far, three small studies on genetic causes of Iranian patients with IRD have been reported \[[@r41],[@r48],[@r49]\].

Compared to the multiple targeted gene panel tests for different subtypes of IRDs that have been developed in the past few years with a detection rate of approximately 50--70% \[[@r50]\], we found similar percentages of pathogenic variants using our panel testing. Haer-Wigman et al. showed that using an in silico gene panel (based on whole exome sequencing) that was performed for 266 Dutch patients with visual impairment, in 52% of the cases, the genetic cause was identified \[[@r51]\]. However, in some studies the detection rate using panel testing was low. For instance, Fu et al. recruited 31 families with autosomal recessive RP and identified the pathogenic variant through a gene panel comprising 163 retinal disease genes. The authors achieved a detection rate of approximately 40% \[[@r52]\].

Variant c.6385A\>G, apart from a predicted amino acid exchange, p.(Ser2129Gly), lowers the strength of a splice donor site of exon 46. A splice assay can shed light on its effect. Moreover, most of the variants detected in the patients are homozygous except four families that we identified as carrying compound heterozygous variants in *RP1*(Gene ID 19888, OMIM [180100](https://www.ncbi.nlm.nih.gov/omim/?term=180100)), *ABCA4*, and *BBS2*(Gene ID 67378, OMIM [615981](https://www.ncbi.nlm.nih.gov/omim/?term=615981)). The most frequently mutated gene was *RPE65*(Gene ID 6121, OMIM [180069](https://www.ncbi.nlm.nih.gov/omim/?term=180069)), mutated in 4/50 (8%) of the families (Figure 1). Sundaresan et al. reported that although the mutations in some genes such as *RPE65* are a common cause of LCA in North America, they are rare in southern India \[[@r53]\]. To determine whether mutations in *RPE65* are a common cause of RP in the Iranian population, we need to screen a larger cohort of RP probands in the future.

Our genetic findings, in particular the recurrence for variants in *CERKL*(Gene ID 375298, OMIM [608381](https://www.ncbi.nlm.nih.gov/omim/?term=608381)), *RPE65*, and *RPGRIP1*(Gene ID 57096, OMIM [605446](https://www.ncbi.nlm.nih.gov/omim/?term=605446)) will aid genetic testing for IRD in the Iranian population. Furthermore, different variants in one gene can cause the same phenotype as, for example, different homozygous missense variants in *GUCY2D* (Gene ID 3000, OMIM [600179](https://www.ncbi.nlm.nih.gov/omim/?term=600179)) in two unrelated patients cause LCA. Similarly, various pathogenic variants in *LRAT* (Gene ID 9227, OMIM [604863](https://www.ncbi.nlm.nih.gov/omim/?term=604863)) and *CRB1*(Gene ID 23418, OMIM [604210](https://www.ncbi.nlm.nih.gov/omim/?term=604210) ) in unrelated patients cause RP. However, the same variant in one gene can cause different phenotypes, such as a homozygous frameshift variant in the *CERKL* gene that led to CRD and RP in two unrelated families. Another example of this category is a homozygous missense variant in *RPGRIP1* that caused LCA in two unrelated patients and CRD in one patient. In addition, different variants in one gene can cause different phenotypes as exemplified by *ABCA4* that causes STGD1 and autosomal recessive (arRP).

Mutations in genes associated with Bardet-Biedl syndrome (BBS), such as BBS1 (Gene ID 582, OMIM [209900](https://www.ncbi.nlm.nih.gov/omim/?term=209900)) and *BBS2*, can also be found in non-syndromic arRP \[[@r54]-[@r56]\]. The variants within these two genes identified in this study are associated with non-syndromic RP as the probands did not show extraocular features.

We identified homozygous *CRB1* variants in two RP probands. One of these missense mutations, p.(Thr745Met), was previously detected in three Iranian RP cases by Ghofrani et al. \[[@r41]\]. Mutations in *CRB1* have been shown to be responsible for 10% of LCA cases in northwestern Europe and 2.5% of arRP cases in the French population \[[@r10],[@r57]\].

Although finding known and new mutations in known IRD-associated genes through cost-effective gene panel testing is important for patients who cannot afford the price of whole exome sequencing (WES) and whole genome sequencing (WGS), WES and WGS provide the opportunity to discover novel genes, as well as copy number variations (CNVs) and noncoding variants in IRD-associated genes \[[@r58]-[@r60]\]. The sequencing costs for this gene panel testing (MIP analysis), excluding the MIP synthesis costs and Sanger sequencing validation, were about €40 per sample, which is 10--20 times lower than the commercial price for WES.

Despite the high yield in this study, for 28% of the patients with IRDs, we still do not know the causal gene defects. The MIP design was based on the non-syndromic IRD-associated genes known in October 2013. In the meantime, another 60 non-syndromic IRD genes have been discovered that together may well explain another 10--15% of IRD cases. In conclusion, we demonstrated that this panel testing, employing MIPs, is a cost-effective targeted NGS-based method with a high detection rate for pathogenic variants in patients with IRDs.

![Relative involvement of 19 inherited retinal disease-associated genes among the 50 probands.](mv-v25-106-f1){#f1}

###### In-silico analysis of the non-truncating pathogenic variants identified in this study.

  Gene      Amino acid change   Number of Probands   Mutationtaster    Polyphen-2          Grantham score   PhyloP score   SIFT          CADD score   ExAC MAF   Known/ Novel variant
  --------- ------------------- -------------------- ----------------- ------------------- ---------------- -------------- ------------- ------------ ---------- ----------------------
  ABCA4     p.(Arg212Cys)       1                    Disease causing   Probably damaging   180              5.2            Deleterious   26.4         0.000117   Known
  ABCA4     p.(Cys1488Arg)      1                    Disease causing   Possibly damaging   180              8.9            Deleterious   21           1.42E-05   Known
  ABCA4     p.(Ser2129Gly)      1                    Disease causing   benign              56               7.9            Tolerated     19.96        N/A        Known
  BBS1      p.(Arg160Gln)       1                    Disease causing   Probably damaging   43               7.9            Deleterious   33           4.12E-05   Known
  BBS2      p.(Val75Gly)        1                    Disease causing   Probably damaging   109              9.1            Deleterious   27.2         N/A        Known
  CEP290    p.(Val2435Gly)      1                    Disease causing   Probably damaging   109              8.4            Deleterious   24.8         N/A        Novel
  CRB1      p.(Thr745Met)       1                    Disease causing   Probably damaging   81               5.5            Deleterious   15           8.26E-05   Known
  CRB1      p.(Cys183Tyr)       1                    Disease causing   Probably damaging   194              7.4            Deleterious   15.9         N/A        Novel
  GUCY2D    p.(Arg795Trp)       1                    Disease causing   Probably damaging   101              1.37           Deleterious   21.7         8.26E-06   Novel
  GUCY2D    p.(Asp406His)       1                    Disease causing   Probably damaging   81               9.1            Deleterious   20.9         N/A        Novel
  LRAT      p.(His163Asp)       1                    Disease causing   Probably damaging   81               7.6            Deleterious   20           N/A        Novel
  PDE6C     p.(Phe538Ile)       1                    Disease causing   Probably damaging   21               7.4            Deleterious   25.1         N/A        Novel
  PDZD7     p.(Arg265Gly)       1                    Disease causing   Possibly damaging   125              2.4            Deleterious   15.1         8.24E-06   Novel
  RPE65     p.(Tyr368His)       2                    Disease causing   Probably damaging   83               8.8            Deleterious   24.4         6.6E-05    Known
  RPGRIP1   p.(Ala436Ser)       3                    Disease causing   Probably damaging   99               5.4            Deleterious   15           N/A        Novel

MAF: Minor allele frequency, N/A: Not available
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The splice donor site predictions (in blue; 5') show a decrease from 91.8 to 80.3 for SpliceSiteFinder-like. There are no scores for the other programs as the 'GC' canonical splice site sequence only is recognized by SpliceSiteFinder-like. A strong cryptic splice donor site at c.6386+27 in intron 47 possibly could be activated in the ABCA4 gene carrying c.6385A\>G. To access the data, click or select the words "[Appendix 1](http://www.molvis.org/molvis/v25/appendices/mv-v25-106-app-1.docx)."
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